Pharmacogenomics · 2014 · 13 citations · 67 references
MedicineGeneticsPharmacologyCancer GeneticsPharmacogeneticsPharmacogenomicsCancer MetabolomicsCancer PharmacogenomicsDrug Metabolism GeneticsDrug Metabolism GenomicsGermline Pharmacogenetic VariationXenobiotic MetabolismCancer Therapy Response VariabilityCommon Genetic VariantsDrug Metabolism PolymorphismsDrug-metabolizing Enzyme VariabilityGenetic Risk VariantsMetabolic Pathway PolymorphismsMetabolism Enzyme PolymorphismsPharmacogenomic Implications
Cytosolic SULT1A1 participates in the bioconversion of a plethora of endogenous and xenobiotic substances. Genetic variation in this important enzyme such as SNPs can vary by ethnicity and have functional consequences on its activity. Most SULT1A1 genetic variability studies have been centered on the SULT1A1*1/2 SNP. Highlighted here are not only this SNP, but other genetic variants associated with SULT1A1 that could modify drug efficacy and xenobiotic metabolism. Some studies have investigated how differential metabolism of xenobiotic substances influences susceptibility to or protection from cancer in multiple sites. This review will focus primarily on the impact of SULT1A1 genetic variation on the response to anticancer therapeutic agents and subsequently how it relates to environmental and dietary exposure to both cancer-causing and cancer-preventative compounds.
67
William B. Jakoby, Daniel M. Ziegler · Journal of Biological Chemistry · 1990 · 413 citations · Full text